Early MRD negativity to predict deepening myeloma response in relapsed/refractory multiple myeloma (RRMM) patients treated with bb2121 anti-BCMA CAR T cells.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Author and article information

Journal

Title: Journal of Clinical Oncology

Abbreviated Title: JCO

Publisher: American Society of Clinical Oncology (ASCO)

ISSN (Print): 0732-183X

ISSN (Electronic): 1527-7755

Publication date Created: May 20 2018

Publication date (Print): May 20 2018

Volume: 36

Issue: 15_suppl

Page: 8024

Affiliations

[1 ]Dana-Farber Cancer Institute, Boston, MA;

[2 ]Sarah Cannon Research Institute, Nashville, TN;

[3 ]Mayo Clinic, Rochester, MN;

[4 ]Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD;

[5 ]Massachusetts General Hospital Cancer Center, Boston, MA;

[6 ]Stanford University School of Medicine, Palo Alto, CA;

[7 ]Mount Sinai Medical Center, New York, NY;

[8 ]Beth Israel Deaconess Medical Center, Boston, MA;

[9 ]Bluebird Bio, Cambridge, MA;

[10 ]Celgene Corporation, Summit, NJ;

[11 ]Hackensack University Medical Center, Hackensack, NJ;

Article

DOI: 10.1200/JCO.2018.36.15_suppl.8024

SO-VID: 8e6ccaee-0884-42ab-9aaf-bf8448b8bc68

History

Data availability:

Comments

Comment on this article

scite_

Cited by 5

See all cited by